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Abstracts
Gregory L. Moneta, MD, Section EditorCardiovascular Effects of Intensive Lifestyle Intervention in Type 2
Diabetes
The Look AHEAD Research Group. N Engl J Med 2013;369:145-54.
Conclusion: Intensive lifestyle intervention focusing on weight loss
does not reduce the rate of cardiovascular events in overweight or obese
adults with type 2 diabetes.
Summary: There are numerous beneﬁts to weight loss. They include
glycemic control, control of risk factors for cardiovascular disease, improved
quality of life, and a decrease in obesity-related coexisting diseases. For these
reasons and others, weight loss is almost universally recommended for over-
weight or obese patients with type 2 diabetes (Clinical Practice Recommen-
dations, American Diabetes Association, 2013). However, although it seems
intuitive that weight loss would reduce risk of cardiovascular morbidity and
mortality in patients with type 2 diabetes, it is actually unknown whether
this is true. A Swedish study showed reduced rates of cardiovascular events
in patients with type 2 diabetes who underwent bariatric surgery (Romeo S
et al, Diabetes Care 2012;35:2613-7). However, the study was not random-
ized, and certainly, results achieved through surgery cannot be generalized
to other methods of weight loss. The authors therefore examine the critical
question: Would intensive lifestyle intervention to achieve weight loss
through caloric restriction and increased physical activity decrease cardiovas-
cular morbidity and mortality among overweight or obese patients with type
2 diabetes? In this study, conducted in 16 centers in the United States, 5145
overweight or obese patients with type 2 diabetes were randomly assigned
to participate in an intensive lifestyle intervention that promoted weight
loss through decreased caloric intake and increased physical activity, the
intervention group, or receive diabetes support and education only, the
control group. The primary outcome was a composite of death from cardio-
vascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospital-
ization for angina occurring over a maximum follow-up of 13.5 years. At
a median follow-up of 9.6 years, the trial was stopped early based on analysis
of futility. Weight loss was greater in the intervention group than the control
group throughout the study (8.6% vs 0.7% at 1 year; 6% vs 3.5% at study
end). The intensive lifestyle intervention also produced greater reductions
in glycated hemoglobin and greater initial improvements in ﬁtness and in
all cardiovascular risk factors except for low-density lipoprotein cholesterol
levels. The primary outcome occurred in 403 patients in the intervention
group and in 418 in the control group (1.83 and 1.92 events/100
person-years, respectively; hazard ratio for the intervention group, 0.95;
95% conﬁdence interval, 0.83-1.09; P ¼ .51).
Comment: The authors point out that the study is not entirely nega-
tive. Although intensive lifestyle intervention compared with diabetes
support did not reduce the risk of cardiovascular morbidity and mortality,
there were other beneﬁts attributable to the intervention in the intervention
group. These included clinically meaningful improvements in glycemic
control, with a lesser percentage of patients requiring insulin treatment,
along with reductions in urinary incontinence, sleep apnea, and depression.
There were also improvements in quality of life, physical functioning, and
mobility. Although it is unfortunate that weight loss itself mediated through
lifestyle intervention does not affect cardiovascular morbidity and mortality
in type 2 diabetic patients, weight loss should still be recommended for such
patients because of a myriad of other associated health beneﬁts.
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic
Attack
Wang Y., Wang Y., Zhao X., et al; and the CHANCE Investigators. N Engl
J Med 2013;369:11-9.
Conclusion: In patients with transient ischemic attack (TIA) or minor
stroke treated #24 hours after onset of symptoms, the combination of
aspirin and clopidogrel is superior to aspirin alone in reducing stroke risk
in the ﬁrst 90 days. The combination does not increase the risk of
hemorrhage.
Summary: After a TIA or a minor stroke, the risk for subsequent
stroke is high. Approximately 10% to 20% of such patients will have a stroke
#3 months after the index event, and most of these strokes will occur within
the ﬁrst 2 days (Kleindorfer D et al, Stroke 2005;36:720-3; and Coull AJ et
al, BMJ 2004:328:326). Aspirin has been shown to have a modest effect for1140secondary stroke prevention. However, aspirin is the only antiplatelet agent
that has been studied in the acute phase of stroke. Large-scale trials of
secondary prevention of ischemic events after stroke have not shown
a beneﬁt of the combination of clopidogrel and aspirin (Bhatt DL et al,
N Engl J Med 2006;354:1706-17; and Diener HC et al, Lancet
2004:364:331-7). Limitations to these studies, however, are that they did
not study the early high-risk period after stroke, included some patients
with moderate stroke severity, and had few, if any, patients with TIA.
This trial, the Clopidogrel in High-risk Patients with Acute Non Disabling
Cerebral Vascular Events (CHANCE), was designed to test the hypothesis
that 3 months of treatment with a combination of clopidogrel and aspirin
would reduce risk of recurrent stroke compared with aspirin alone in
patients with acute high-risk TIA or minor ischemic stroke. This was
a randomized, double-blind, placebo-controlled trial conducted at 114
centers in China, in which 5170 patients were randomly assigned#24 hours
after onset of a minor ischemic stroke or high-risk TIA to combination
therapy with clopidogrel (300-mg initial dose, followed by 75 mg/d for
90 days) and aspirin (75 mg/d for the ﬁrst 21 days) or to a placebo plus
aspirin (75 mg/d for 90 days). All patients on day 1 received open-label
aspirin at a clinician-determined dose of 75 to 300 mg. Primary outcome
was ischemic stroke or hemorrhage during 90 days of follow-up using an
intention-to-treat analysis. Cox proportional hazard models were used to
assess treatment differences, with study center as a random effect. In the clo-
pidogrel-aspirin group, stroke occurred in 8.2% of patients compared with
11.7% of patients in the aspirin-alone group (hazard ratio, 0.68; 95% conﬁ-
dence interval, 0.57-0.81; P < .001). Moderate or severe hemorrhage
occurred in seven patients (0.3%) in the clopidogrel-aspirin group and in
eight patients (0.3%) in the aspirin-alone group (P ¼ .73). Rate of hemor-
rhagic stroke was 0.3% in each group.
Comment: This study was conducted exclusively at Chinese centers.
Chinese patients have a higher incidence of large-artery intracranial athero-
sclerosis than Western populations (Wong LK et al, Int J Stroke
2006;1:158-9) and also appear to have a higher prevalence of genetic poly-
morphisms effecting clopidogrel (Rosemery J et al, Curr Clin Pharmacol
2007;2:93-109). In addition, the study excluded patients who underwent
carotid revascularization. Nevertheless, if one looks at Figure 1, plotting
the probability of survival free of stroke after the initial event, one sees
that the beneﬁt with the use of the combination of clopidogrel and aspirin
over aspirin alone occurs almost entirely within the ﬁrst few days of the
initial event. Therefore, when patients present with a minor stroke or
a TIA, it seems that early stroke recurrence, regardless of whether revascu-
larization is planned, is best prevented by early administration of a combina-
tion of aspirin and clopidogrel rather than use of aspirin alone.
Reestablishment of the Endothelial Lining by Endothelial Cell
Therapy Stabilizes Experimental Abdominal Aortic Aneurysms
Franck G., Dai J., Fifre A., et al. Circulation 2013;127:1877-87.
Conclusion: Endothelial cell (CE) seeding may be an effective
therapy to arrest abdominal aortic aneurysm (AAA) expansion.
Summary: AAA is the third leading cause of cardiovascular death.
Rupture is proportional to external diameter. There is evidence intraluminal
thrombus affects the structural and cellular composition of the AAA wall
(Kazi M et al, J Vasc Surg 2003;38:1283-92). Intraluminal thrombus in
an AAA is associated with loss of the luminal EC monolayer. ECs are known
to play a major role in maintenance of vascular integrity through complex
mechanisms controlling thrombosis, inﬂammation, and matrix coverage.
The casual relationship between aortic diameter expansion and the presence
of thrombus and the lack of EC coverage is an aspect of AAA pathology that
has not been well explored. The authors hypothesized that re-endotheliali-
zation would modulate aortic wall destruction and ultimately stabilize
AAAs. To test this hypothesis, they evaluated the effect of local seeding of
rat aortic ECs or peripheral blood-derived outgrowth ECs on AAA evolu-
tion. Rat aortic ECs (n ¼ 30) or serum-free medium (controls; n ¼ 29)
were seeded endovascularly immediately (day 0) or 14 days after surgery
in a rat AAA model. Rat aortic EC seeding prevented AAA formation and
stabilized formed AAAs at 28 days (diameter increased at day 0+28, 51% 6
6% vs 83% 6 6%; day 14+28, 4% 6 4% vs 22% 6 6% in rat aortic
EC-treated models vs controls, respectively; P < .01). The stabilizing effect
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proteolysis, and reconstitution of a new aortic wall with smooth muscle cells
and extra cellular matrix. ECs exerted their healing properties through para-
crine mechanisms involving up-regulation of endothelium-derived stabi-
lizing factors and recruitment of resident vascular cells. They did not
appear to directly participate in aortic wall repair. Transplantation of
outgrowth ECs (n ¼ seven) reduced by 30% progression of AAAs and
restored abluminal endothelium at 28 days compared with controls (n ¼
nine).
Comment: The authors demonstrate that it is possible using EC seed-
ing techniques to institute recovery of the luminal endothelial lining in an
animal model of AAA. In addition, this new endothelial lining through para-
crine effects appears to result in stabilization of the AAA. It has been previ-
ously known that re-endothelialization of denuded arteries can modulate
the vascular smooth muscle cell phenotype in neointimal hyperplasia. This
study, however, is the ﬁrst to extend this concept to stabilization of
AAAs. It is a unique contribution and perhaps sheds new light on AAA path-
ophysiology and, from the clinical perspective, suggests ultimately a new
mechanism of potentially arresting the growth of AAAs.
Economic Analysis of a Randomized Trial of Percutaneous
Angioplasty, Supervised Exercise or Combined Treatment for
Intermittent Claudication due to Femoropopliteal Arterial Disease
Mazari FAK., Kahn JA., Carradice D., et al. Br J Surg 2013;100:1172-9.
Conclusion: Supervised exercise therapy (SET) is the most cost-effec-
tive ﬁrst-line treatment for intermittent claudication. SET in combination
with percutaneous angioplasty (PTA) is also more cost-effective than PTA
alone.
Summary: This study reports the economic analysis of the authors’
previous study comparing PTA, SET, and combined treatment for intermit-
tent claudication (IC) due to femoropopliteal disease (Mazari FA et al, Br J
Surg 2012;99:39-48). In the original trial, patients with IC secondary to
femoropopliteal disease were randomized to receive PTA, SET, or the
combination of PTA plus SET. Clinical and quality of life indicators were
recorded before therapy and at 1, 3, 6, and 12 months after intervention.
The Short Form-6D health utilities index was calculated from the Short-
Form 36 and plotted. Quality-adjusted life-years (QALYs) were generated
through calculations of the area under the curve. Costs were calculated
using the British National Health Service 2009 to 2010 payment-by-results
tariffs and the National Institute for Health Research Clinical Research
Network Investigation pricing index and adjusted for reinterventions.
Cost per QALY and incremental costs were calculated. A sensitivity analyses
was also performed. A total of 178 patients were randomized (PTA, 60;
SET, 60; PTA+SET, 58). In all treatment groups, there was signiﬁcant
improvement in the SF-6D index (P < .001). There was, however, no
signiﬁcant difference between treatments in mean (95% conﬁdence interval)
QALYs gained (PTA: 0.620 [0.588-0.652]; SET: 0.627 [0.597-0.660];
PTA+SEP: 0.649 [0.622-0.675]). The adjusted mean cost per procedure
was signiﬁcantly higher for PTA (€7301.74) than for SET (€3866.49) and
PTA+SET (€6911.68; P < .001). Costs per QALY were higher for PTA
(€11777.00) compared with SET (€6147.04) and PTA+SET (€10649.74).
This was due to the PTA-alone group undergoing more reinterventions
than the PTA+SET group (nine vs zero reinterventions). QALYs were
lost when PTA alone was used as ﬁrst-line treatment compared with SEP
or PTA+SET. Results were robust and valid in sensitivity analyses.
Comment: On the basis of this analysis, one has to wonder why payers
are willing to pay for percutaneous procedures for treatment of IC but are not
willing to pay for SET for treatment of IC? If one is going to pay for percu-
taneous procedures for treatment of IC, it would seem reasonable to require
that patients treated with percutaneous procedures for IC also be enrolled in
a SET program and that the SET program be paid for as well. The data here
suggest that if one is willing to pay for percutaneous procedures for IC,
requiring SET will actually result in overall decreased costs.
Homocysteine Improves Risk Stratiﬁcation in Patients Undergoing
Endarterectomy for Asymptomatic Internal Carotid Artery Stenosis
Duschek N., Ghai S., Sejkic F., et al. Stroke 2013;44:2311-4.
Conclusion: High plasma homocysteine (Hcy) levels suggest older
patients with asymptomatic carotid stenosis might beneﬁt from intensive
medical therapy rather than from carotid endarterectomy (CEA).
Summary: CEA for asymptomatic patients with high-grade carotid
stenosis (ACAS) has become very controversial. Medical therapy has
advanced, and beneﬁt from CEA for ACAS may be reduced and, some
contend, perhaps eliminated (Abbott AL, Stroke 2009;40:e573-83; and
Spence JD et al, Arch Neurol 2010;67:180-6). The authors of this article
point out that myocardial infarction is responsible for up to 50% ofperioperative deaths after CEA and causes more postoperative deaths than
stroke (Hertzer NR, Arison R. J Vasc Surg 1985;2:661-8). Therefore,
potential candidates for risk stratiﬁcation for carotid surgery include those
with cardiovascular morbidity. A potential candidate for risk stratiﬁcation
is the amino acid Hcy, which is acknowledged as a risk factor for cardiovas-
cular adverse events. In this study, the authors assessed plasma levels of total
Hcy (tHcy) as a biomarker to predict postoperative survival in patients with
ACAS. The study was a prospective, nonrandomized, case series from 2003
to 2012 in which 214 consecutive patients, 130 aged <75 years and 84 aged
$75 years, who underwent CEA for asymptomatic internal carotid artery
stenosis were observed for 8.5 years for occurrence of death after CEA as
the primary end point. Major cardiovascular risk factors and tHcy were
used for computation of prognostic indices. Kaplan-Meier curves were
used to estimate cumulative survival of prognostic indices-based quintiles.
tHcy had a signiﬁcant effect on postoperative survival (P < .0001). tHcy-
based quintiles of prognostic indices showed a better prediction of survival
than age alone. The result was reclassiﬁcation of 17 patients (20.2%) aged
>75 years as ﬁt for surgery but also indicated a high risk for 19 patients
(14.6%) aged <75 years. CEA could not be advised in 79.8% of patients
aged >75 years because of a signiﬁcantly reduced 5-year survival rate.
Comment: In essence, the authors’ data suggest best medical treat-
ment that includes B-vitamins, taking into account folate status, vitamin
B12 status, and renal function, may be a preferred path over CEA in older
hyperhomocysteinemic patients with ACAS. The data, however, lack
a control group of patients with high-grade ACAS who did not undergo
CEA and in whom adverse events were correlated to tHcy levels. As such,
Hcy levels alone are not likely to emerge, based on this study, as a primary
determinant of eligibility for CEA for ACAS. However, the concept that
modifying overall cardiovascular risks in patients with ACAS should be
a concern equal to or greater than neurologic outcome in this patient group
seems quite reasonable.
Blood Pressure and Cholesterol Control in Hypertensive
Hypercholesterolemic Patients: National Health and Nutrition
Examination Surveys 1988-2010
Egan BM., Li J., Qanungo S., et al. Circulation 2013;128:29-41.
Conclusion: There has been signiﬁcant progress in concomitant
hypertension and hypercholesterolemia control. However, signiﬁcant op-
portunities for improvement still remain.
Summary: Most hypertensive patients are also afﬂicted with hypercho-
lesterolemia. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),
lowering low-density lipoprotein cholesterol (LDL-C) from 133 mg/dL at
baseline to 87 mg/dL in hypertensive patients reduced coronary heart
disease 36% compared with placebo-treated patients (Sever PS et al, Lancet
2003;361:1149-58). In the Air Force/Texas Coronary Atherosclerosis
Prevention Study, treatment with lovastatin (20-40 mg/d), compared
with placebo, reduced LDL-C from 156 to 115 mg/dL and reduced coro-
nary heart disease 38% in hypertensive patients (Downs JR, et al, JAMA
1998; 279:1615-22). The National Health and Nutrition Examination
Surveys (NHANES) are used to address compliance issues relevant to control
of cardiovascular disease. In this study, the authors examined concurrent
hypertension and cholesterol control in the NHANES surveys from 1988
to 2010. Speciﬁcally, surveys from 1988 to 1994, 1999 to 2004, and
2005 to 2010 were analyzed. Hypertension was deﬁned by a blood pressure
$140/$90 mm Hg, current medication treatment, and twice-told hyper-
tension status; blood pressure <140/<90 deﬁned control. Hypercholester-
olemia was deﬁned by Adult Treatment Panel (ATP) III criteria based on 10-
year coronary heart disease risk, LDL-C levels, and non-high-density lipo-
protein cholesterol (HDL-C) levels, with values below diagnostic thresholds
deﬁning control. Across surveys, 60.7% to 64.3% of hypertensive patients
were also hypercholesterolemic. From 1988 to 1994 and 2005 to 2010,
control of LDL-C rose 9.2% to 45.4%. Control of concomitant hypertension
and LDL-C rose 5% to 30.7%, and control of combined hypertension and
non-HDL-C cholesterol rose 1.8% to 26.9%. The factors associated with
concomitant hypertension, LDL-C, and non-HDL-C control were statin
use (odds ratio [OR], 10.7), antihypertensive medications (OR, 3.32), age
per 10-year increase (OR, 0.77), two or more health care visits per year
(OR, 1.90), black race (OR, 0.59), Hispanic ethnicity (OR 0.62), cardiovas-
cular disease (OR, 0.44), and diabetes mellitus (OR, 0.54).
Comment: In essence, the data indicate use of statins and hyperten-
sive medications improve blood pressure and cholesterol control in hyper-
tensive hypercholesterolemic patients. This seems obvious, but perhaps
not so obvious is that the percentage of this population achieving control
is increasing over time. What also is not so obvious is that to achieve better
cardiovascular disease control in the United States population, targeting
patients with combined hypertension and hypercholesterolemia who are
also elderly, minorities, or who have diabetes perhaps may be facilitated
